ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10
ProQR Therapeutics N.V. - Ordinary Shares (PRQR)
Last proqr therapeutics n.v. - ordinary shares earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
proqr.com
Company Research
Source: GlobeNewswire
Key Updates ProQR receives Fast Track designation by the U.S. Food and Drug Administration (FDA). Closer interaction with FDA could potentially accelerate the development of QR-110 in patients with Leber’s Congenital Amaurosis Type 10 (LCA 10).LCA 10 is one of the most prevalent forms of gene-related blindness in children worldwide and currently there are no therapies commercially available or in clinical development.QR-110 is currently in clinical development with the planned Phase 1/2 open-label trial (PQ-110-001) that will assess the safety, tolerability, pharmacokinetics and efficacy of multiple administrations of QR-110 in one eye of each patient and will include approximately 6 adults and 6 children with LCA 10.Top-line trial results are expected in 2018. LEIDEN, the Netherlands, May 31, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for QR-110, the lead
Show less
Read more
Impact Snapshot
Event Time:
PRQR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRQR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRQR alerts
High impacting ProQR Therapeutics N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PRQR
News
- ProQR Therapeutics (NASDAQ: PRQR) had its price target raised by analysts at Citigroup Inc. from $1.80 to $2.00. They now have a "buy" rating on the stock.MarketBeat
- ProQR Therapeutics (NASDAQ: PRQR) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- ProQR Therapeutics (NASDAQ: PRQR) had its price target raised by analysts at Chardan Capital from $2.00 to $2.50. They now have a "buy" rating on the stock.MarketBeat
- ProQR Therapeutics (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- ProQR Announces Year End 2023 Operating and Financial ResultsGlobeNewswire
PRQR
Earnings
- 11/7/23 - Miss
PRQR
Sec Filings
- 3/13/24 - Form 20-F
- 3/13/24 - Form 6-K
- 2/15/24 - Form 6-K
- PRQR's page on the SEC website